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1  | INTRODUC TION
Brugada syndrome (BrS) is an autosomal dominant inherited ar‐
rhythmia syndrome characterized by ST‐segment elevation in the 
right precordial leads without obvious evidence of ischemia, electro‐
lyte disturbances, or structural heart disease. It predisposes patients 
to major arrhythmic events (MAE) including sustained ventricular 
tachycardia, ventricular fibrillation, appropriate implantable cardio‐
verter defibrillator (ICD) shocks, aborted cardiac arrest, and sudden 
cardiac death (Brugada & Brugada, 1992; Priori et al., 2013). There 
 
Received:	23	March	2018  |  Revised:	22	May	2018  |  Accepted:	5	June	2018
DOI: 10.1111/anec.12589
O R I G I N A L  A R T I C L E
SCN5A mutation status increases the risk of major arrhythmic 
events in Asian populations with Brugada syndrome: 
systematic review and meta-analysis
Pattara Rattanawong1,2*  | Jirat Chenbhanich3* | Poemlarp Mekraksakit4 |  
Wasawat Vutthikraivit5  | Pakawat Chongsathidkiet6  | Nath Limpruttidham1 |  
Narut Prasitlumkum1  | Eugene H. Chung7
*These authors contributed equally to this work. 
1University of Hawaii Internal Medicine 
Residency Program, Honolulu, Hawaii
2Faculty of Medicine Ramathibodi 
Hospital, Mahidol University, Bangkok, 
Thailand
3Department of Internal 
Medicine, Metrowest Medical Center, 
Framingham, Massachusetts
4Department of Medicine, Phramongkutklao 
College of Medicine, Bangkok, Thailand
5Department of Medicine, Texas Tech 
University Health Sciences Center, Lubbock, 
Texas
6Department of Pathology, Duke University 
Medical Center, Durham, North Carolina
7Department of Internal 
Medicine, University of Michigan Medical 
School, Michigan Medicine, Ann Arbor, 
Michigan
Correspondence
Pattara Rattanawong, 1133 Waimanu St, 
#2007, Honolulu, HI 96814.
Email: pattara.rattanawong@gmail.com
Abstract
Background: Brugada syndrome (BrS) is an inherited arrhythmic disease linked to 
SCN5A mutations. It is controversial whether SCN5A mutation carriers possess a 
greater risk of major arrhythmic events (MAE). We examined the association of 
SCN5A mutations and MAE in BrS patients.
Methods: We comprehensively searched the databases of MEDLINE and EMBASE 
from inception to September 2017. Included studies were published cohort and 
case–control studies that compared MAE in BrS patients with and without SCN5A 
mutations. Data from each study were combined using the random‐effects model. 
Generic inverse variance method of DerSimonian and Laird was employed to calcu‐
late the risk ratios (RR) and 95% confidence intervals (CI).
Results: Seven studies from March 2002 to October 2017 were included (1,049 BrS 
subjects). SCN5A mutations were associated with MAE in Asian populations 
(RR = 2.03, 95% CI: 1.37–3.00, p = 0.0004, I2 = 0.0%), patients who were sympto‐
matic (RR = 2.66, 95% CI: 1.62–4.36, p = 0.0001, I2 = 23.0%), and individuals with 
spontaneous type‐1 Brugada pattern (RR = 1.84, 95% CI: 1.05–3.23, p = 0.03, 
I2 = 0.0%).
Conclusions: SCN5A mutations in BrS increase the risk of MAE in Asian populations, 
symptomatic BrS patients, and individuals with spontaneous type‐1 Brugada pattern. 
Our study suggests that SCN5A mutation status should be an important tool for risk 
assessment in BrS patients.
K E Y W O R D S
Brugada syndrome, genetic, major arrhythmic events, SCN5A, sudden cardiac death
[Correction added on 05 September, 2018, 
after first online publication: The article title 
has been amended from ‘SCN5A Mutation 
Increases the Risk of Major Arrhythmic Events 
in Asian Population of Brugada Syndrome: 
Systematic Review and Meta‐analysis’ has 
been changed to ‘SCN5A mutation status 
increases the risk of major arrhythmic events 
in Asian populations with Brugada syndrome: 
systematic review and meta‐analysis’.]
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are geographic differences in the prevalence of BrS: it varies from 0.5 
to 4 per 1,000 in Asian countries such as Thailand, the Philippines, 
Japan,	 and	 Singapore	 (Rattanawong	 et	 al.,	 2016;	 Rattanawong,	
Ngarmukos, et al., 2017), whereas the prevalence is less than 0.2 
per 1,000 in the western hemisphere (Kamakura, 2013). It is more 
common in men and can be induced by fever, with the prevalence 
of fever‐induced BrS of approximately 2%–4% (Kamakura, 2013; 
Rattanawong et al., 2016).
The most common identifiable genetic defect in BrS lies in the 
SCN5A gene, which encodes the α‐subunit of the NaV1.5 cardiac so‐
dium channel and accounts for 14%–26% of the cases (Chen et al., 
1998; Yamagata et al., 2017). More than 300 mutations in the SCN5A 
gene	have	been	linked	to	the	syndrome	(Juang	&	Horie,	2016).	The	
only preventive measure for sudden cardiac death in BrS is ICD im‐
plantation; thus, risk stratification to select the patient in whom ICD 
is appropriate is crucial (Probst et al., 2010). The use of SCN5A mu‐
tation status to prognosticate the risk of MAE in BrS patients has 
been controversial (Adler et al., 2016): some studies showed positive 
results (Makarawate et al., 2017; Nishii et al., 2010; Yamagata et al., 
2017), while others failed to correlate the mutation to subsequent 
MAE (Andorin et al., 2016; Gehi, Duong, Metz, Gomes, & Mehta, 
2006; Priori et al., 2002; Probst et al., 2010). The goal of this sys‐
tematic review and meta‐analysis was to examine the association of 
SCN5A mutations and MAE in BrS patients.
2  | METHOD
2.1 | Search strategy
Two investigators (WV and PC) independently searched for pub‐
lished studies indexed in MEDLINE and EMBASE databases from in‐
ception to September 2017 using a search strategy that included the 
terms “SCN5A,” “mutation,” and “Brugada.” Only English language 
publications were included. A manual search for additional pertinent 
studies and review articles using references from retrieved articles 
was also completed.
2.2 | Inclusion criteria
The eligibility criteria included the following:
1. Cohort study (prospective or retrospective) or case–control 
study reporting the incidence of MAE in BrS patients with 
and without SCN5A mutations
2. Calculation of relative risk, hazard ratio, odds ratio, incidence 
ratio, or standardized incidence ratio with 95% confidence inter‐
vals (CI) or provision of sufficient raw data for these calculations 
were provided.
3. Use of BrS participants without SCN5A mutations as controls.
Study eligibility was independently determined by two investi‐
gators	(JC	and	PM)	and	any	discrepancies	were	resolved	by	mutual	
consensus. Newcastle‐Ottawa quality assessment scale was used 
to evaluate each study’s quality. The scale uses a star system (0–9) 
to evaluate three domains: recruitment and selection of the partic‐
ipants, similarity and comparability between the groups, and ascer‐
tainment of the outcome of interest among cohort studies. Higher 
scores represent higher study quality (Stang, 2010).
2.3 | Data extraction
A standardized data collection form was used to obtain the fol‐
lowing information from each study: title of study, name of first 
author, year of study, year of publication, country of origin, num‐
ber of participants, demographic data of participants, method 
used to identify cases and controls, methods used to diagnose 
the outcomes of interest (SCN5A mutation and MAE), methods 
to verify if the variants were disease‐causing, and average du‐
ration of follow‐up with confounders that were adjusted effect 
estimates with 95% CI and covariates that were adjusted in the 
multivariable analysis.
To ascertain the accuracy, all investigators independently per‐
formed this data extraction process. Any data discrepancy was re‐
solved by referring back to the original articles.
2.4 | Statistical analysis
We performed a meta‐analysis of the included cohort studies 
using a random‐effects model. The extracted studies were ex‐
cluded from the analysis if they did not present an outcome in each 
intervention group or did not have enough information required 
for continuous data comparison. We pooled the point estimates 
from each study using the generic inverse‐variance method of 
DerSimonian and Laird (1986). The heterogeneity of effect size 
estimates across these studies was quantified using the I2 statis‐
tic and Q statistic. For the Q statistic, substantial heterogeneity 
was defined as p < 0.10. The I2 statistic ranges in value from 0% 
to 100% (I2 < 25%, low heterogeneity; I2 = 25%–50%, moderate 
heterogeneity; and I2 > 50%, substantial heterogeneity; Higgins, 
Thompson, Deeks, & Altman, 2003). A sensitivity analysis was 
performed to assess the influence of the individual studies on the 
overall results by omitting one study at a time. We used a sequen‐
tial omitting strategy, as described by Patsopoulos, Evangelou, 
and Ioannidis (2008), to examine whether overall estimates were 
influenced by the substantial heterogeneity observed. Publication 
bias was assessed using a funnel plot and Egger’s regression 
test (p < 0.05 was considered significant; Sterne & Egger, 2001). 
Potential sources of heterogeneity from clinical characteristics 
were analyzed with subgroup analysis and were compared with 
meta‐regression. Pooled risk ratio (RR), sensitivity analysis, fun‐
nel plot, and forest plot were performed using Review Manager 
(RevMan) [Computer program]. Version 5.3. Copenhagen: The 
Nordic Cochrane Centre, The Cochrane Collaboration, 2014. 
Egger test was performed using the Stata SE 14.1 software from 
StataCorp LP.
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3  | RESULTS
3.1 | Description of included studies
Our search strategy yielded 382 potentially relevant articles (227 
articles from EMBASE and 155 articles from MEDLINE). After exclu‐
sion of duplicates, 253 articles underwent title and abstract review. 
Two hundred and eleven articles were excluded at this stage as they 
were not cohort studies and they were not conducted in patients 
with BrS, leaving 42 articles for full‐length article review. Thirty‐five 
articles were excluded because they did not report the outcome of 
interest or they did not have a control group. Therefore, seven pro‐
spective cohort studies of BrS patients were included in this meta‐
analysis. Figure 1 outlines the search and literature review process. 
The clinical characteristics and summary of included studies are 
provided in Table 1. The Newcastle‐Ottawa scales of the included 
studies are described in the Table 1.
3.2 | Meta-analysis results
Seven studies from March 2002 to October 2017 were included in 
this meta‐analysis involving 1,049 subjects with BrS (302 patients 
with SCN5A mutations and 747 patients without SCN5A muta‐
tions). Five studies revealed an increased MAE among BrS patients 
with SCN5A mutations (Andorin et al., 2016; Conte et al., 2015; 
Makarawate et al., 2017; Nishii et al., 2010; Yamagata et al., 2017) 
with one of the five studies (Makarawate et al., 2017) achieving 
statistical significance. The pooled analysis demonstrated a nonsig‐
nificant increased risk of MAE in BrS patients with SCN5A mutations 
compared	to	those	without	the	mutation,	with	a	pooled	RR of	1.50	
(95% CI: 0.93–2.41, p = 0.10, I2 = 38.0%). A forest plot of this meta‐
analysis is shown in Figure 2.
In subgroup analysis among ethnicities, three studies (two studies 
from	Japan	and	one	study	from	Thailand)	were	included	in	Asian	pop‐
ulations (Makarawate et al., 2017; Nishii et al., 2010; Yamagata et al., 
2017) involving 486 subjects with BrS (80 patients with SCN5A mu‐
tations and 406 patients without SCN5A mutations). All three studies 
revealed increased MAE among BrS patients with SCN5A mutations 
(Makarawate et al., 2017; Nishii et al., 2010; Yamagata et al., 2017) 
with one study (Makarawate et al., 2017) achieving statistical signifi‐
cance. The pooled analysis demonstrated a significant increased risk 
of MAE in Asian BrS patients with SCN5A mutations compared to 
those without the mutation (RR = 1.78, 95% CI: 1.23–2.58, p = 0.002, 
I2 = 0%). A forest plot of this meta‐analysis is shown in Figure 2.
In Caucasian cohorts, four studies were included in the analysis 
(Andorin et al., 2016; Conte et al., 2015; Eckardt et al., 2005; Priori et 
al., 2002) involving 563 subjects with BrS (222 patients with SCN5A 
mutations and 341 patients without SCN5A mutations). One study 
revealed a nonsignificant increase in MAE among BrS patients with 
SCN5A mutations (Andorin et al., 2016). The pooled analysis did not 
demonstrate an increased risk of MAE in Caucasian BrS patients 
with SCN5A mutations compared to those without the mutation 
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(RR = 0.78, 95% CI: 0.34–1.80, p = 0.57, I2 = 15%). A forest plot of 
this meta‐analysis is shown in Figure 2.
In symptomatic BrS patients, there were four studies (Andorin 
et al., 2016; Makarawate et al., 2017; Nishii et al., 2010; Yamagata et 
al., 2017) involving 271 subjects with BrS (60 patients with SCN5A 
mutations and 211 patients without SCN5A mutations). Every study 
revealed an increased MAE among symptomatic BrS patients with 
SCN5A mutations with two studies (Makarawate et al., 2017) achiev‐
ing statistical significance. The pooled analysis demonstrated a 
significant increased risk of MAE in Asian BrS patients with SCN5A 
mutations compared to those without the mutation (RR = 1.78, 95% 
CI: 1.23–2.58, p = 0.0001, I2 = 23%). A forest plot of this meta‐anal‐
ysis is shown in Figure 3a. The pooled analysis of asymptomatic 
BrS patient showed an increased but non‐significant risk of MAE 
(RR = 1.85, 95% CI: 0.60–5.68, p = 0.28, I2 = 0%). However, only two 
studies involving 290 subjects with asymptomatic BrS (78 patients 
with SCN5A mutations and 212 patients without SCN5A mutations) 
reported data suitable for meta‐analysis (Figure 3b).
Two studies reported on spontaneous type‐1 Brugada pattern 
(Andorin et al., 2016; Yamagata et al., 2017) involving 327 subjects 
with BrS and SCN5A status (68 patients with SCN5A mutations and 
259 patients without SCN5A mutations). The pooled analysis demon‐
strated a significant increased risk of MAE in BrS patients who 
presented with spontaneous type‐1 Brugada pattern with SCN5A 
mutations compared to those without the mutation (RR = 1.84, 95% 
CI: 1.05–3.23, p = 0.03, I2 = 0.0%). A forest plot of this meta‐analysis 
is shown in Figure 3c.
3.3 | Sensitivity analysis
To assess the stability of the result, we conducted a sensitivity analysis 
by omitting one study at a time. We used a sequential omitting strat‐
egy, as described by Patsopoulos and colleagues, to examine whether 
overall estimates were influenced by the substantial heterogeneity ob‐
served (Patsopoulos et al., 2008). In the overall analysis, when omitting 
the study reported by Eckardt et al., the pooled analysis demonstrated 
a significantly increased risk of MAE in BrS patients with SCN5A muta‐
tions	compared	to	those	without	the	mutation,	with	a	pooled	RR of	1.65	
(95% CI: 1.09–2.51, p = 0.019, I2 = 24.3%) as well as the study reported 
by Priori et al. 1.89 (95% CI: 1.31–2.74, p = 0.001, I2 = 0.0%) (Figure 5). 
In the subgroup analysis, none of the results was significantly altered.
3.4 | Publication bias
To investigate potential publication bias, we examined the contour‐
enhanced funnel plot of the included studies in assessing change 
in the log odd ratio of death or composite outcome (Figure 4). The 
vertical axis represents study size (standard error) while the hori‐
zontal axis represents effect size (log odds ratio). The distribution 
of studies on both sides of the mean was symmetrical. Egger’s test 
was nonsignificant for small‐study bias in overall analysis (p = 0.518), 
symptomatic BrS (p = 0.787), Caucasians (p = 0.756), and Asians 
(p = 0.095). Egger’s test could not be performed for asymptomatic 
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BrS, and spontaneous type‐1 pattern subgroups as there were only 
two studies. Meta‐regression confirmed that the studies published 
before 2010 were significant sources of heterogeneity (p = 0.035) 
but available verification status of SCN5A disease‐causing variants 
was not a significant source of heterogeneity (p = 0.968).
4  | DISCUSSION
We have analyzed 1,049 subjects with BrS from seven studies and 
showed an association between the presence of SCN5A mutations 
and risk for developing MAE in Asian population, patients with 
symptomatic BrS, and individuals with spontaneous type‐1 Brugada 
pattern. Increased but not statistically significant risk was found in 
Caucasians, all BrS individuals, and asymptomatic BrS subjects. The 
nonsignificant association in overall BrS may be due to interstudy 
and intrastudy demographic and genetic variations.
After performing subgroup analyses, the association between 
SCN5A status and MAE in some groups appeared more significant 
with decreased heterogeneities. Overall BrS individuals analysis 
showed moderate heterogeneity of 38.0%, whereas subgroups anal‐
ysis showed low heterogeneity (0% in Asian, 23% in symptomatic, 
0% in spontaneous type‐1, 15% in Caucasian, and 0% in asymptom‐
atic). These results reflected the effect of individual basic charac‐
teristics to the outcome of MAE, which is more homogenized when 
analyzed by each subgroup.
Additionally, to explore the possible sources of heterogeneity 
in our meta‐analysis, we used sensitivity analysis by omitting one 
study at a time. When omitting the studies published by Eckardt et 
al. and Priori et al. from the overall analysis, we found a significantly 
increased risk of MAE in BrS patients with SCN5A mutations com‐
pared	to	those	without	the	mutations,	with	a	pooled	RR of	1.65	(95%	
CI: 1.09–2.51, p = 0.019) and 1.89 (95% CI: 1.31–2.74, p = 0.001, 
I2 = 0.0%), consecutively (Figure 5). Heterogeneity decreased from 
moderate (38.0%) to low (24.3%) when we omitted only Eckardt et 
al. and from moderate (38.0%) to none (0.0%) when we omitted only 
Priori et al. These sensitivity analysis results can be explained by sev‐
eral possible reasons. First, since the early publications in 2002 and 
2005, more than 300 novel SCN5A mutations have been discovered 
(Juang	&	Horie,	2016).	Hence,	Eckardt	et	al.	(2005)	and	Priori	et	al.	
(2002) may not have studied several mutations included in our study 
and meta‐regression confirmed that the studies published before 
2010 are significant sources of heterogeneity (p = 0.035). Second, 
their study populations were mostly asymptomatic Caucasian indi‐
viduals (58% in Eckardt et al. and 72% in Priori et al.). The subgroup 
analyses from our study indicated significant associations of SCN5A 
mutations and MAE in symptomatic and Asian groups, but not in the 
Caucasian group. These aforementioned factors are thus suggestive 
of existing heterogeneity interfering with the results from our analy‐
ses. The cause of heterogeneity is also noted in the study performed 
by Makarawate et al. (2017) which correlated SCN5A mutation sta‐
tus with cardiac conduction disturbances and resultant appropriate 
ICD shocks. Their study included a geographically and genetically 
isolated population: most patients were of northeastern Thai origin; 
only symptomatic patients were included; and only two polymor‐
phisms were identified (R1193Q and H558R). A degree of pathoge‐
nicity of these two variants were questionable and may be more, or 
less, malignant than those reported in other studies.
It is well recognized that a history of aborted cardiac arrest is one 
of the strongest predictors for future MAE in BrS patients (Eckardt 
et al., 2005; Priori et al., 2002; Probst et al., 2010; Yamagata et al., 
2017); in fact, the current guidelines recommends that those who 
survive episodes of cardiac arrest should undergo ICD implanta‐
tion (Priori et al., 2013) as the risk of subsequent cardiac events 
was highest among this patient subgroup and was estimated as 
7.7% per year in one study (Probst et al., 2010). On the other hand, 
the risk of MAE in asymptomatic BrS individuals is low, approxi‐
mately 0.5% per year (Probst et al., 2010). Other reported potential 
risks include male sex, presence of spontaneous ST‐segment ele‐
vation in the precordial leads, positive electrophysiological study, 
F I G U R E  2   Forest plot of the included studies assessing the association between SCN5A mutation and major arrhythmic events and fatal 
arrhythmia among Asian, Caucasian, and overall analysis
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presence of atrial fibrillation, and certain electrocardiographic 
conduction abnormalities such as prolonged P‐wave, prolonged 
QRS duration, and fragmented QRS (Chen et al., 1998; Gehi et al., 
2006; Priori et al., 2002; Rattanawong, Riangwiwat, et al., 2017; 
Yamagata et al., 2017). Priori et al. demonstrated that the pres‐
ence of both syncope and spontaneous ST‐segment elevation has 
F I G U R E  3   Forest plot of the included studies assessing the association between SCN5A mutation and major arrhythmic events and fatal 
arrhythmia in subgroup analysis of (a) symptomatic BrS, (b) asymptomatic BrS, and (c) spontaneous type‐1 BrS
F I G U R E  4   Funnel plot of SCN5A 
mutation and major arrhythmic events in 
(a) overall analysis, Asian, and Caucasian, 
(b) symptomatic, (c) asymptomatic, and 
(d) spontaneous type‐1. Circles represent 
observed published studies
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a sensitivity of 36% and a high specificity of 94% in predicting the 
occurrence of cardiac arrest in BrS patients (Priori et al., 2002). On 
the contrary, many studies have assessed family history of sudden 
cardiac death as a predictor for poorer outcomes, and the results 
were reproducibly unrevealing (Gehi et al., 2006; Makarawate et 
al., 2017; Nishii et al., 2010; Priori et al., 2002). Clinicians have long 
been intrigued by the concept of using SCN5A mutation status to 
predict MAE in BrS patients.
Adler et al. (2016) have recently reviewed the risk stratification 
strategy in patients with BrS and stated that, according to the large 
registries, the use of genetic data to risk stratify BrS patients are 
not well‐defined and challenging. Even though a risk score based 
on the mutations and other polymorphisms has been developed 
(Sommariva et al., 2013), the authors suggested that the tool needs 
to be validated before being adopted. In 2006, Gehi et al. analyzed 
383 patients from two publications (Eckardt et al., 2005; Priori et al., 
2002) and found no link between SCN5A mutations and increased 
risk of sudden cardiac death, syncope, or ICD shock (relative risk 
0.60, CI: 0.29–1.26). We speculate that the nonsignificant result in 
their study was due to a lower number of recruited patients, lower 
number of included studies, and limited power to identify a minimal 
increase in risk. To our knowledge, our study is the first meta‐analy‐
sis to demonstrate the potential utilization of SCN5A mutation in the 
risk stratification scheme, particularly in certain subgroups, of BrS.
SCN5A mutations were reported in approximately 14%–26% of 
BrS patients and known as the most common BrS‐associated gene 
(Chen et al., 1998; Yamagata et al., 2017). Almost 300 SCN5A mu‐
tations have been identified in BrS, including missense mutations, 
nonsense mutations, nucleotide insertion/deletions, and splice site 
mutations, and the number of SCN5A mutations is still increasing 
(Juang	 &	 Horie,	 2016).	 An	 SCN5A mutation does not necessarily 
indicate BrS (Probst et al., 2009). The functional loss of NaV1.5 
cardiac sodium channel with subsequent reduced sodium current 
is typically described in BrS patients with SCN5A mutations	(Juang	
& Horie, 2016). This is supported by the fact that BrS‐associated 
SCN5A mutations usually result in frameshift errors, splice‐site de‐
fects, or premature stop codons that lead to nonfunctional channels 
(Chen et al., 1998). BrS‐causing missense mutations were observed 
to be nonfunctional due to either disrupted protein trafficking to 
the cell membrane or impaired sodium conductance (George, 2005). 
Although some missense mutations are functional, they may cause 
defective gated properties of the channels involving activation and/
or inactivation kinetics (Andorin et al., 2016; Rook et al., 1999). 
Meregalli et al. corroborated this speculation by studying 147 mu‐
tation‐positive BrS individuals and divided them into three groups: 
(a) those with prematurely truncated proteins (group 1); (b) those 
with missense mutations resulting in significantly (>90%) reduced 
peak sodium current (group 2); and (c) those with missense muta‐
tions	resulting	in	mildly	(≤90%)	reduced	peak	sodium	current	(group	
3) (Meregalli et al., 2009). They found that patients in group 1 and 
group 2, in which drastic peak sodium current were noted, devel‐
oped a more severe conduction disorders. The underlying electro‐
physiological mechanisms of how altered sodium current causes BrS 
are still under investigation, and two models have been proposed 
(Meregalli, Wilde, & Tan, 2005). In the “repolarization disorder” 
model, the defective sodium channel reduces the myocardial so‐
dium current and causes a disproportionate shortening of the right 
ventricular epicardial action potentials, leading to an exaggerated 
transmural (i.e., epicardium‐to‐myocardium) voltage gradient and 
the characteristics finding on electrocardiogram (George, 2005; 
Juang	&	Horie,	 2016;	 Smits	 et	 al.,	 2002).	 The	 “depolarization	dis‐
order” model theorizes that conduction delay in the right ventric‐
ular outflow tract, with respect to the right ventricle, causes the 
electrocardiogram changes in BrS. The arrhythmogenicity of BrS is 
likely multifactorial and other pathophysiology may play a role: for 
instance, a recent study proposed epicardial surface fibrosis and re‐
duced gap junction expression in the right ventricular outflow tract 
as arrhythmogenic mechanisms in BrS (Nademanee et al., 2015).
F I G U R E  5   Sensitivity analysis graph 
to explore source of heterogeneity by 
omitting one study at a time0.72 1.500.93 2.41 2.74
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When compared to SCN5A‐negative BrS patients, those with 
SCN5A mutations tend to exhibit significantly longer conduction in‐
tervals on electrocardiogram, such as PQ or His‐to‐ventricle inter‐
vals, and more fragmented QRS, both at baseline and throughout the 
follow‐up (Makarawate et al., 2017; Nishii et al., 2010; Rattanawong, 
Riangwiwat, et al., 2017; Smits et al., 2002; Yokokawa et al., 2007). 
These parameters were also predictive of the presence of the mu‐
tation:	 for	example,	PQ	duration	of	≥210	milliseconds	had	a	sensi‐
tivity of 48% and a specificity of 98% for detecting SCN5A mutation 
in BrS patients (Smits et al., 2002). The prognostic value of SCN5A 
status has become more apparent in recent well‐designed studies. 
In a study of 415 BrS patients reported by Yamagata et al. (2017), 
SCN5A mutation carriers tended to experience their cardiac events 
more frequently and at younger ages. Apart from history of aborted 
cardiac arrest, harboring the mutation was the only independent 
predictor of MAE, with a hazard ratio of 2.0 (95% CI: 1.0–3.8). They 
also found that mutations in the pore region of the NaV1.5 cardiac 
sodium channel were more associated with MAE (Yamagata et al., 
2017). Hence, these studies have confirmed the genotype‐pheno‐
type correlations in SCN5A‐positive BrS individuals, both at electro‐
cardiographic level and clinical level.
Recently, Nademanee et al. (2011) reported right ventricular 
outflow tract epicardial ablation in recurrent symptomatic BrS. The 
indication for right ventricular outflow tract epicardial ablation in 
symptomatic BrS is still unclear. Right ventricular outflow tract fi‐
brosis and conduction delay were identified in carriers of SCN5A 
mutations (Meregalli et al., 2009). Moreover, age‐related fibrosis has 
also been seen in mouse models of SCN5A	mutation	(Jeevaratnam	et	
al., 2012; Royer et al., 2005). Therefore, SCN5A mutations may con‐
tribute to substrate changes which may be treatable with epicardial 
ablation. In our study, we found that SCN5A mutations in symptom‐
atic BrS is twofold associated with MAE compared to symptomatic 
Brugada syndrome without SCN5A mutations. SCN5A mutation 
status may therefore enhances risk stratification of symptomatic 
Brugada syndrome.
4.1 | Limitations
Although most recruited studies were of high quality, we recognize 
there are some limitations to our analysis. First, the studies are het‐
erogeneous as discussed earlier. The potential sources of heterogene‐
ity include age and gender of participants, definitions of MAE in each 
study, follow‐up duration, inclusion of mutation‐positive screened 
family members or of asymptomatic carriers, geographic difference, 
and recruiting protocol (e.g., multicenter registry vs. single center). 
Second, genetic heterogeneity also existed among studies. For in‐
stance, Yamagata et al. (2017) identified 55 different mutations in 60 
affected individuals in their multicenter cohort, whereas Makarawate 
et al. (2017) found only two different mutated alleles in 13 SCN5A 
mutation carriers. However, since BrS is uncommon and large‐scale 
genetic studies have been rarely performed, the possibility of small‐
study bias due to the small number of included studies and small sam‐
ple size is not negligible. A larger study with a more homogeneous 
population is needed to confirm our results. Unfortunately, there 
was not enough information reported in two articles that we could 
use to calculate multivariate adjusted RR. Risk ratios were calcu‐
lated based on number of the patients without multivariate adjust‐
ment. Third, large genomic imbalances, such as copy‐number variants 
(CNVs) in SCN5A, were recently shown to underlie a portion of geno‐
type‐negative patients and should be screened (Mademont‐Soler et 
al., 2016; Sonoda et al., 2018). However, all of the recruited studies 
have used traditional methods of sequencing which could not detect 
CNVs; hence, the control group may include those CNV‐harboring 
sequencing‐negative patients and did not truly represent unaffected 
individuals. Fourth, three (Makarawate et al., 2017; Priori et al., 2013; 
Yamagata et al., 2017) of seven studies reported information on how 
the authors verified if the variants were disease‐causing (Table 1); 
however, meta‐regression confirmed that verification status of SCN5A 
disease‐causing variants was not a significant source of heterogeneity 
in overall results. Lastly, this is a meta‐analysis of observational studies 
with the inherent limitation of being able to confirm an association, but 
not a causal relationship.
5  | CONCLUSION
From our study, we found that mutation status may help predict 
MAE and guide treatment decisions in certain subgroups of BrS, es‐
pecially in Asian population, symptomatic patients, and individuals 
with spontaneous type‐1 Brugada pattern. The presence of SCN5A 
mutations may be an important tool to prognosticate risk and guide 
treatment in patients with BrS in the future.
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